INTI (Inhibitor Therapeutics) EPS (Basic) : $-0.02 (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics EPS (Basic)?

Inhibitor Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.02.

Inhibitor Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.02.

Inhibitor Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was $-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.02.

During the past 12 months, Inhibitor Therapeutics's average EPS without NRIGrowth Rate was -205.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -88.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -0.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Inhibitor Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 59.10% per year. The lowest was -119.30% per year. And the median was 29.05% per year.

Inhibitor Therapeutics EPS (Basic) Historical Data

The historical data trend for Inhibitor Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibitor Therapeutics EPS (Basic) Chart

Inhibitor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.01

0.03

-0.02

Inhibitor Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-	-0.01	-	-	-

Inhibitor Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Inhibitor Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.026	-	0)	/	171.950
	=	-0.02

Inhibitor Therapeutics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.731	-	0)	/	172.324
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

Inhibitor Therapeutics (OTCPK:INTI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Inhibitor Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4905 South West Shore Boulevard, Tampa, FL, USA, 33611-3329

Website

https://www.inhibitortx.com

Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Executives

Black Robe Capital Llc	10 percent owner	900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii	10 percent owner	1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman	director, 10 percent owner	1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii	10 percent owner	C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc	10 percent owner	12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez	director	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty	10 percent owner, officer: See Remarks	C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara	officer: CFO and Treasurer	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie	director	4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin	director	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab	director, officer: Chairman of the Board	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606